BASINGSTOKE, England and PHILADELPHIA, July 4 /PRNewswire-FirstCall/ –
Shire Limited (LSE:SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, will announce second quarter 2008 earnings on
Thursday 31 July 2008
Results press release will be issued at: 12:00 BST / 07:00 EDT
Investor meeting and conference call time: 14:30 BST / 09:30 EDT
Investor & Analyst meeting and conference call:
Angus Russell, Chief Executive Officer, Graham Hetherington, Chief
Financial Officer, Mike Cola, President, Specialty Pharmaceuticals and Sylvie
Grégoire, President, Human Genetic Therapies will host the investor and
analyst meeting and conference call at 14:30 BST/9:30 EDT.
The meeting will take place at Holborn Bars, 138-142 Holborn, London EC1
2NQ.
Please email claire.rowell@fd.com to register to attend this meeting in
London.
The details of the conference call are as follows:
UK and International dial in +44-(0)-203-023-4496
US dial in: +1-866-966-5335
Password/Conf ID: Shire
Live Webcast:
The call will also be available live over the Internet via audio webcast,
accessible through www.shire.com in the investors section. A slide
presentation to accompany the call will also be available on the Shire
website.
Replay:
A replay of the presentation will be available for two weeks by phone and
by webcast for one year. Details are as follows:
UK and International dial in +44-(0)-208-196-1998
US dial in +1-866-583-1035
Pin code 3008632
Webcast replay: http://www.shire.com, in the investors
section
Notes to Editors
SHIRE LIMITED
Shire’s strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit and hyperactivity
disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and
renal diseases. The structure is sufficiently flexible to allow Shire to
target new therapeutic areas to the extent opportunities arise through
acquisitions. Shire’s in-licensing, merger and acquisition efforts are
focused on products in niche markets with strong intellectual property
protection either in the US or Europe. Shire believes that a carefully
selected portfolio of products with strategically aligned and relatively
small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website:
http://www.shire.com.
For further information please contact:
Investor Relations
Souheil Salah (Rest of the World) +44-1256-894-160
Emily Berish (North America) +1-484-595-8546
SOURCE Shire Ltd